Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.39 |
| ▸ | LSS | P48449 | 5/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25188963 | 1.00 | POLB (0.40) | POLBCHRM2CHRM3LSSHSD11B1 | |
| SCHEMBL3717754 | 0.84 | CYP2A6 (0.36) | POLBCHRM2CHRM3LSSNPC1 | |
| SCHEMBL25503917 | 0.83 | ALDH1A1 (0.48) | LSSRAB9AMEN1KMT2A | |
| SCHEMBL30442241 | 0.83 | ALDH1A1 (0.48) | LSSRAB9AMEN1KMT2A | |
| SCHEMBL28206973 | 0.78 | CHRM2 (0.48) | POLBCHRM2CHRM3MAPT | |
| SCHEMBL25192577 | 0.78 | JAK2 (0.42) | POLBLSSNPC1RAB9AMEN1 | |
| SCHEMBL25192574 | 0.78 | JAK2 (0.42) | POLBLSSNPC1RAB9AMEN1 | |
| SCHEMBL4168246 | 0.75 | MEN1 (0.43) | MEN1KMT2A | |
| SCHEMBL5025729 | 0.75 | JAK2 (0.37) | POLBNPC1RAB9A | |
| SCHEMBL25356633 | 0.75 | KDM1A (0.48) | CHRM2CHRM3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400587-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS INC (US) | 2024-12-05 | — | — | US | disclosed |
| EP-4430052-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-12091426-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | NURIX THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240018162-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023086399-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091426-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | TTK, HIPK1, CLK1 | POLB 1715/4885CHRM2 4833/4885CHRM3 4807/4885 |
| US-20240400587-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, CLK1 | POLB 1715/4885CHRM2 4833/4885CHRM3 4807/4885 |
| US-20240018162-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, CLK1 | POLB 1715/4885CHRM2 4833/4885CHRM3 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.